Norfloxacin-resveratrol eutectic loaded hemostatic sponge and preparation method thereof
Through the complexation of norfloxacin and resveratrol with gelatin and sodium alginate, a hemostatic sponge with antibacterial and healing function is solved, and the shortcomings of existing hemostatic sponges in antibacterial and healing are achieved and efficient hemostatic cessation is achieved and promote wound healing effects.
Patent Information
- Application Number
- CN202411069048.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
Existing hemostatic sponges have limitations in rapidly controlling bleeding and preventing wound infection, and lack antibacterial and pro-healing functions, making it difficult to achieve efficient hemostatic and promote wound healing at the same time.
Norfloxacin and resveratrol are combined with gelatin and sodium alginate to form a hemostatic sponge loaded with eutectics, combining its antibacterial and healing effects to improve hygroscopicity, permeability and biosafety.
It has achieved an efficient hemostatic sponge preparation with dual antibacterial and healing effects, which has good hygroscopicity, permeability and biosafety, suitable for industrial production, and simplified the preparation process.
Smart Images

Figure CN118976139A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug co-crystals, and in particular to a norfloxacin co-crystal-loaded hemostatic sponge having advantages in hygroscopicity and permeability, and a preparation method and application thereof. Background Art
[0002] Massive blood loss can lead to a high mortality rate and cause serious complications. Therefore, quickly controlling bleeding, preventing bacterial infection of the wound, and effectively promoting wound healing are the keys to the survival of patients with severe bleeding.
[0003] The special porous structure of the hemostatic sponge ensures its high liquid absorption rate, allowing it to absorb a large amount of blood in a short period of time. It also forms a hemostatic mechanism through red blood cell (RBC) accumulation, platelet stimulation and changes in fibrinogen structure. Clinically, it can effectively treat irregular, narrow or deep wounds caused by capillaries, etc.
[0004] Drug-drug cocrystals are a subset of drug cocrystals and have great potential for synergistic therapeutic effects and improved biopharmaceutical properties. At the same time, as a special form of drug cocrystals, they can also improve the solubility and mechanical properties of the corresponding drugs.
[0005] The mechanism of action of quinolone antibiotics mainly targets DNA helicase and topoisomerase, inhibiting bacterial growth by blocking the replication and transcription processes. They have strong antibacterial activity against both Gram-negative and Gram-positive bacteria and are one of the most widely used broad-spectrum antibiotics.
[0006] Polyphenol compounds are natural antioxidants. Due to the high hydroxylation in their structure, they have antibacterial, anti-fibrotic, antioxidant and anti-inflammatory properties. In addition, they also have anti-cancer and antiviral activities, so they have the potential to treat various types of diseases.
[0007] The present invention will study drug-drug co-crystals by combining antibiotic molecules with good antibacterial activity with polyphenol compounds with healing-promoting effects, and combine hemostatic sponge preparations to develop a highly efficient hemostatic sponge with both antibacterial and healing-promoting effects.
[0008] Norfloxacin (also known as Noroxin, Fulgram), its chemical name is 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, and its chemical formula is C 16 H 18 FN3O3, molecular weight is 319.24, chemical structure is as follows:
[0009] Summary of the invention
[0010] The purpose of the present invention is to apply the drug co-crystal technology to the important field of developing new norfloxacin co-crystals and their preparations, and provide a norfloxacin co-crystal, a co-crystal-loaded gelatin-sodium alginate hemostatic sponge and a preparation method thereof, which have good hygroscopicity, permeability, antibacterial and healing-promoting effects. In combination with the hemostatic sponge preparation, a high-efficiency hemostatic sponge with both antibacterial and healing-promoting effects is developed.
[0011] To achieve the above object, the technical solution adopted by the present invention is:
[0012] The present invention provides a norfloxacin cocrystal having advantages in hygroscopicity, permeability, antibacterial property and healing promotion, including a cocrystal formed by combining norfloxacin with a cocrystal former; the cocrystal former is resveratrol, i.e., a norfloxacin and resveratrol cocrystal. A hemostatic sponge having antibacterial and healing promotion efficacy includes a hemostatic sponge formed by a composite of a norfloxacin-resveratrol cocrystal loaded on gelatin and sodium alginate, i.e., a cocrystal-loaded gelatin-sodium alginate hemostatic sponge, which has good antibacterial and healing promotion activity, good biological safety and good hemostatic performance.
[0013] Preferably, the X-ray powder diffraction spectrum of the norfloxacin-resveratrol cocrystal has characteristic peaks represented by angle 2θ (°): 5.84, 6.64, 7.90, 9.74, 12.06, 13.26, 13.58, 14.10, 15.02, 15.58, 16.32, 16.70, 18.66, 19.16, 19.74, 20.55, 20.86, 21.94, 22.64, 22.92, 24.06, 25.00, 25.48, 25.90, 26.32, 26.70, 27.78, 28.46, 29.58, 29.88, 30.96, 31.92, 32.50, 35.81, 39.42, 40.88, 41.96, with an error tolerance of ±0.2°.
[0014] Preferably, the thermogravimetric analysis (TGA) spectrum of the norfloxacin-resveratrol co-crystal shows a 4.56% weight loss at 37-100° C., which is attributed to a desolvation phenomenon, and the co-crystal is a hydrate.
[0015] Preferably, the differential scanning calorimetry spectrum of the norfloxacin-resveratrol cocrystal shows a peak = There is an endothermic peak at 95.49℃, which is attributed to the desolvation endothermic peak.
[0016] Preferably, in the norfloxacin-resveratrol co-crystal, norfloxacin and resveratrol are present in a molar ratio of 2:0.5.
[0017] Preferably, the eutectic-loaded gelatin-sodium alginate hemostatic sponge has a liquid absorption rate of 10.11, a porosity of 0.96, a shape fixation ratio of 0.39, and a shape recovery ratio of 0.75.
[0018] The preparation method of norfloxacin-resveratrol cocrystal powder comprises the following specific steps: weighing equimolar norfloxacin (100 mg) and resveratrol (94 mg), adding 5 mL of ethanol and 0.2 mL of water, stirring on a magnetic stirrer for 24 hours at room temperature to obtain a white turbid liquid, and then centrifuging it in a centrifuge at a speed of 8000 r for 5 minutes, discarding the supernatant, and drying the precipitate in a vacuum drying oven at 50°C to obtain a white powder.
[0019] The preparation method of the eutectic-loaded gelatin-sodium alginate hemostatic sponge comprises the following specific steps: adding 20 mg / mL gelatin and 20 mg / mL sodium alginate at room temperature for limited swelling, heating and stirring, standing to remove bubbles, freezing at -80°C for 12 hours, and then vacuuming for 12 hours, soaking the obtained freeze-dried sample in a 20 mg / mL calcium chloride aqueous solution for cross-linking for 2 hours, and freeze-drying again to obtain a white gelatin-sodium alginate hemostatic sponge. The norfloxacin-resveratrol eutectic is loaded by an immersion method to obtain a eutectic-loaded gelatin-sodium alginate hemostatic sponge.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The co-crystal formed by norfloxacin and resveratrol is a pharmaceutically acceptable co-crystal former synthesized co-crystal, which has the dual effects of antibacterial and promoting healing, and has good hygroscopicity and permeability. It is combined with a hemostatic sponge with good biosafety and hemostatic effect to design a high-efficiency hemostatic sponge preparation with dual effects of antibacterial and promoting healing.
[0022] On the other hand, the preparation methods of the norfloxacin cocrystal and the cocrystal-loaded gelatin-sodium alginate hemostatic sponge of the present invention are simple, have good repeatability, and are suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the X-ray powder diffraction (XRPD) spectrum of the norfloxacin-resveratrol cocrystal prepared in Example 1;
[0024] Figure 2 The differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) spectra of the norfloxacin-resveratrol cocrystal prepared in Example 1;
[0025] Figure 3 is a unit cell diagram of single crystal X-ray powder diffraction (SCXRD) of the norfloxacin-resveratrol co-crystal prepared in Example 2;
[0026] Figure 4 is a bar graph of the equilibrium solubility of norfloxacin and norfloxacin-resveratrol cocrystal in 37°C buffer (pH 7.8) of Example 3;
[0027] Figure 5 The powder dissolution curves of norfloxacin and norfloxacin-resveratrol co-crystal in 37°C buffer (pH 7.8) for 6 hours in Example 4;
[0028] Figure 6 The hygroscopicity graph of norfloxacin and norfloxacin-resveratrol cocrystal under the condition of relative humidity of 80%±2% in Example 6;
[0029] Figure 7 This is a graph showing the antibacterial MIC test results of the norfloxacin-resveratrol co-crystal of Example 8;
[0030] Figure 8 This is a graph showing the coagulation test results of the eutectic-loaded gelatin-sodium alginate hemostatic sponge of Example 9;
[0031] Fig. 9 This is a graph showing the results of the SD rat skin healing experiment using the eutectic-loaded gelatin-sodium alginate hemostatic sponge of Example 10. DETAILED DESCRIPTION
[0032] In order to make the contents of the present invention easier to understand, the technical scheme of the present invention is further described below in conjunction with specific embodiments, but the present invention is not limited thereto. All technologies implemented based on the above contents of the present invention are included in the scope of protection of the present invention. Unless otherwise specified, the raw materials and reagents used in the embodiments are commercially available products, and the reagents, instruments or operating steps not described herein are all contents that can be routinely determined by ordinary technicians in the field.
[0033] The present invention provides a norfloxacin cocrystal having advantages in hygroscopicity, permeability, antibacterial property and healing promotion, including a cocrystal formed by combining norfloxacin with a cocrystal former; the cocrystal former is resveratrol, i.e., a norfloxacin and resveratrol cocrystal. A hemostatic sponge having antibacterial and healing promotion efficacy includes a hemostatic sponge formed by a composite of a norfloxacin-resveratrol cocrystal loaded on gelatin and sodium alginate, i.e., a cocrystal-loaded gelatin-sodium alginate hemostatic sponge, which has good antibacterial and healing promotion activity, good biological safety and good hemostatic performance.
[0034] Embodiment 1:
[0035] Preparation method of norfloxacin-resveratrol cocrystal:
[0036] Weigh equimolar amounts of norfloxacin (100 mg) and resveratrol (94 mg), add 5 mL of ethanol and 0.2 mL of water, and stir on a magnetic stirrer at room temperature for 24 h to obtain a white turbid liquid. Centrifuge it at 8000 r for 5 min, discard the supernatant, and dry the precipitate in a vacuum drying oven at 50°C to obtain a white powder.
[0037] In this example, the X-ray powder diffraction spectrum of the obtained norfloxacin-resveratrol cocrystal is shown in Figure 1 , with characteristic peaks expressed in angle 2θ (°): 5.84, 6.64, 7.90, 9.74, 12.06, 13.26, 13.58, 14.10, 15.02, 15.58, 16.32, 16.70, 18.66, 19.16, 19.74, 20.55, 20.86, 21.94, 22.64, 22.92, 24.06, 25.00, 25.48, 25.90, 26.32, 26.70, 27.78, 28.46, 29.58, 29.88, 30.96, 31.92, 32.50, 35.81, 39.42, 40.88, 41.96, with an error tolerance of ±0.2°.
[0038] In this embodiment, the thermal analysis spectrum of norfloxacin-resveratrol cocrystal is shown in Figure 2 The thermogravimetric analysis (TGA) spectrum showed a 4.56% weight loss at 37-100°C, which was attributed to desolvation and the eutectic was a hydrate. The differential scanning calorimetry spectrum showed that peak = There is an endothermic peak at 95.49℃, which is attributed to the desolvation endothermic peak.
[0039] Embodiment 2:
[0040] Comprehensive attachment Figure 3 Shown is the single crystal X-ray diffraction structure of norfloxacin-resveratrol cocrystal
[0041] In this embodiment, the crystal structure parameters of norfloxacin-resveratrol co-crystal are shown in the following table:
[0042]
[0043] In this embodiment, the norfloxacin-resveratrol cocrystal belongs to the triclinic system, the space group is P-1 and Z=4, and its unit cell contains 2 norfloxacin molecules, 0.5 resveratrol molecules, and 1 water molecule.
[0044] Embodiment 3:
[0045] Comprehensive attachment Figure 4 As shown, the equilibrium solubility experiment of norfloxacin-resveratrol cocrystal
[0046] In this example, in order to study the equilibrium solubility of norfloxacin and norfloxacin-resveratrol cocrystal in pH 7.4 buffer, the specific experimental method is as follows: an excess of sample powder was added to 1 mL of pH 7.4 buffer, and after shaking in a constant temperature shaker at 37°C for 24 hours, 0.5 mL of solution was taken from each system, filtered with a 0.22 μm pore size nylon filter membrane, and the concentrations of norfloxacin and resveratrol were determined by high performance liquid chromatography.
[0047] In this example, the equilibrium solubility results of norfloxacin and norfloxacin-resveratrol cocrystal in pH 7.4 buffer are as follows:
[0048] Equilibrium solubility (mg / mL) NFX 0.20 NFX-RES(NFX) 0.32 RES 0.042 NFX-RES(RES) 0.10
[0049] As can be seen from the table, in the pH environment of pH 7.4 buffer as body fluid, it was found that the equilibrium solubility of norfloxacin in the norfloxacin-resveratrol cocrystal was increased by 1.60 times, and the equilibrium solubility of resveratrol was increased by 2.42 times. Therefore, the norfloxacin-resveratrol cocrystal increased the solubility of norfloxacin and resveratrol.
[0050] Embodiment 4:
[0051] Powder dissolution experiment of norfloxacin-resveratrol cocrystal
[0052] In this example, in order to study the powder dissolution behavior of norfloxacin, resveratrol and norfloxacin-resveratrol cocrystal in pH 7.4 buffer, the dissolution rate at 37°C was analyzed. The specific experimental method was as follows: an excess of norfloxacin, resveratrol and norfloxacin-resveratrol cocrystal powders were respectively added to a glass bottle containing a pH 7.4 buffer dissolution medium, the water bath temperature was set to 37±0.5°C, the stirring speed was 200rpm, and samples were taken at preset time points (1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 300, 360min). After taking 600 μL of the supernatant, an equal volume of fresh dissolution medium was added in time, and the supernatant was immediately filtered with a 0.22 μm filter and appropriately diluted and tested for concentration by HPLC.
[0053] In this example, the powder dissolution results of norfloxacin, resveratrol and norfloxacin-resveratrol cocrystal in pH 7.4 buffer are as follows: Figure 5 As shown:
[0054] In this example, the powder dissolution results of norfloxacin, resveratrol and co-crystal in PBS buffer (pH 7.4) are as follows:
[0055] In pH 7.4 buffer, the norfloxacin powder gradually dissolved and maintained at the highest concentration with a solubility of 0.74 mg / mL. The final concentration of the norfloxacin component dissolved in the norfloxacin-resveratrol cocrystal powder was 0.68 mg / mL.
[0056] In pH 7.4 buffer, norfloxacin powder dissolved rapidly, reaching a maximum concentration of 0.74 mg / mL within the first 15 min. The time for the norfloxacin component in the norfloxacin-resveratrol cocrystal powder to reach its peak value shifted to 60 min.
[0057] In pH 7.4 buffer, resveratrol powder gradually dissolved and maintained at the highest concentration with a solubility of 0.059 mg / mL. The final concentration of the resveratrol component dissolved in the norfloxacin-resveratrol cocrystal powder was 0.10 mg / mL.
[0058] Under pH 7.4 buffer, the resveratrol powder reached the maximum concentration of 0.059 mg / mL at 60 min and maintained at the same level. The time for the resveratrol component in the norfloxacin-resveratrol cocrystal powder to reach the peak was still 60 min.
[0059] In summary, the powder was dissolved in PBS buffer (pH 7.4), and it was found that the dissolution rate of norfloxacin in the cocrystal slowed down and the solubility decreased slightly, while the dissolution rate of the resveratrol component remained unchanged and the solubility increased.
[0060] Embodiment 5:
[0061] Experimental study on oil-water partition coefficient of norfloxacin-resveratrol cocrystal
[0062] In this example, the oil-water partition coefficient was determined by the shake flask method, using n-octanol as the oil phase and pH 7.4 PBS buffer as the water phase. 7.4 Test.
[0063] In this embodiment, the experimental results of the oil-water partition coefficient of norfloxacin-resveratrol co-crystal are as follows:
[0064] Oil-water partition coefficient NFX -1.11 NFX-RES(NFX) -0.69
[0065] It can be seen from the table that in the pH 7.4 PBS buffer system, the oil-water partition coefficient of norfloxacin is -1.11, and the oil-water partition coefficient of norfloxacin-resveratrol cocrystal is -0.69. The formation of cocrystal is expected to improve the permeability of norfloxacin.
[0066] Embodiment 6:
[0067] Dynamic Vapor Sorption Experiment of Norfloxacin-Resveratrol Cocrystal
[0068] In this embodiment, the hygroscopicity of norfloxacin and norfloxacin-resveratrol cocrystal was evaluated by dynamic vapor adsorption experiment. The humidity in the instrument was changed in a gradient at intervals of 10% RH. The equilibrium standard was set to a mass change of less than 0.02% / 10min for the sample to be tested, and the maximum equilibrium time was 360min. Two humidity change cycles were performed in this experiment, and the changes in RH were: 50%→95%→0%→95%→0%.
[0069] In this embodiment, the results of the dynamic vapor adsorption experiment of norfloxacin-resveratrol cocrystal are shown in the attached Figure 6 As shown:
[0070] In this embodiment, the results of the dynamic vapor adsorption experiment of norfloxacin-resveratrol cocrystal are as follows: under the condition of relative humidity of 80%±2%, the hygroscopicity of norfloxacin is very strong, which can reach 14.28%, and it is a very hygroscopic drug. The hygroscopicity of norfloxacin-resveratrol cocrystal is 1.58%, which is a slightly hygroscopic drug. The establishment of the cocrystal system helps to reduce the hygroscopicity of the drug itself and provides a guarantee for the drug itself to maintain a stable crystal form.
[0071] Embodiment 7:
[0072] Hemolysis experiment of norfloxacin-resveratrol cocrystal
[0073] In this example, seven groups of drug solutions with concentration gradients of 0.1, 0.08, 0.05, 0.02, 0.01, 0.005, and 0.001 μmol / mL were prepared with 0.9% NaCl solution, 0.5 mL of red blood cell suspension was taken and added together with 0.5 mL of sample solutions of different concentrations into a 2 mL centrifuge tube for mixing, and the same amount of red blood cell suspension was added to 0.5 mL of deionized water and 0.5 mL of 0.9% NaCl solution, respectively, as experimental positive and negative controls.
[0074] In this example, the results of the norfloxacin-resveratrol cocrystal hemolysis experiment are as follows:
[0075] Concentration (μmol / mL) Hemolysis rate 0.001 0.62 0.005 0.90 0.01 0.86 0.02 0.86 0.05 0.77 0.08 0.64 0.1 0.64
[0076] It can be seen from the table that within the experimental range, the hemolysis rate of the norfloxacin-resveratrol cocrystal was lower than 1.5%, and almost no hemolysis occurred, indicating that the cocrystal had good biosafety.
[0077] Embodiment 8:
[0078] Antibacterial MIC experiment of norfloxacin-resveratrol cocrystal In this example, Pseudomonas aeruginosa and Staphylococcus aureus were diluted to 10 6CFU / mL, dilute the sample solution with LB liquid culture medium to a 60 μmol / mL (2×) sample-culture medium mixture, add 100 μL LB liquid culture medium to the second to twelfth wells of the 96-well plate, take 200 μL 60 μmol / mL (2×) sample-culture medium mixture and add it to the first well, then take 100 μL sample-culture medium mixture from the first well and add it to the second well, mix well, take 100 μL of the mixed sample-culture medium mixture and add it to the third well, mix well and so on, dilute the sample solution by two times, and finally take 100 μL of the mixed sample-culture medium mixture from the twelfth well and discard it.
[0079] Replace the sample solution with acetonitrile-DMSO mixture (acetonitrile: DMSO = 1:1) and repeat the above steps as control group 1. Add 200 μL LB liquid culture medium to the blank well as control group 2. Add 100 μL diluted bacterial solution to each well of the 96-well plate, that is, the initial concentration of the sample is 30 μmol / mL. Place the 96-well plate in a constant temperature incubator at 37°C for 24 hours, take pictures and record the MIC value.
[0080] In this embodiment, the antibacterial MIC test results of norfloxacin-resveratrol cocrystal are shown in the attached Figure 7 As shown:
[0081] In this embodiment, the antibacterial MIC experimental results of norfloxacin-resveratrol cocrystal are as follows: for Staphylococcus aureus, the MIC value of norfloxacin is 1.87 μmol / mL, the MIC value of norfloxacin-resveratrol cocrystal is consistent with that of norfloxacin, both are 1.87 μmol / mL, and the antibacterial activity is consistent with that of NFX; for Pseudomonas aeruginosa, the MIC value of norfloxacin is 0.47 μmol / mL, the MIC value of norfloxacin-resveratrol cocrystal decreases to 0.23 μmol / mL, and the antibacterial activity is higher than that of norfloxacin.
[0082] Embodiment 9:
[0083] Coagulation experiment of eutectic-loaded gelatin-sodium alginate hemostatic sponge
[0084] In this embodiment, the hemostatic sponge was preheated at 37°C for 5 minutes, 0.1 mL of blood was added to the hemostatic sponge, and then 10 μL of 0.2 mol / L calcium chloride solution (the calcium chloride solution was prepared from physiological saline) was immediately added, and 10 mL of deionized water was slowly added after 5 minutes, and the mixture was shaken in a 37°C constant temperature shaker, and the solution was taken out and centrifuged. The absorbance was measured at 540 nm using an enzyme marker. The blank group was the control group (0.1 mL of blood was added to 10 mL of deionized water), and the reference value was the absorbance A measured at the same wavelength. control =100.
[0085] In this example, the coagulation test results of the eutectic-loaded gelatin-sodium alginate hemostatic sponge are shown in the attached figure. Figure 8 As shown:
[0086] In this embodiment, the coagulation test results of the eutectic-loaded gelatin-sodium alginate hemostatic sponge are as follows: the coagulation index of the hemostatic sponge is less than 21%, which means that the coagulation index is relatively low and the coagulation effect is relatively good.
[0087] Embodiment 9:
[0088] Skin healing experiment of SD rats with eutectic-loaded gelatin-sodium alginate hemostatic sponge
[0089] In this embodiment, rats were anesthetized by intraperitoneal injection of 10% chloral hydrate solution, and the back hair was shaved off to make a wound with a diameter of about 7 mm on each side. A sponge (diameter 7 mm) was sterilized and attached to the back of the rat and fixed with sterile gauze and adhesive tape. Each rat with a fixed hemostatic sponge was regularly changed on days 0, 2, 4, 6, and 8, and photos of all wounds were taken with a camera on days 0, 2, 5, and 10 to measure the wound area.
[0090] In this example, the results of the eutectic-loaded gelatin-sodium alginate hemostatic sponge SD rat skin healing experiment are shown in the attached Fig. 9 As shown:
[0091] In this embodiment, the results of the eutectic-loaded gelatin-sodium alginate hemostatic sponge SD rat skin healing experiment are as follows: the healing rate of the drug-loaded hemostatic sponge is higher than that of the blank hemostatic sponge, and the presence of the eutectic component can accelerate the wound contraction rate.
[0092] It should be noted that, unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by ordinary technicians in the field to which the present invention belongs, and all patents and publications involved in the present invention are referenced. Although any methods and materials similar or identical to those described in the present invention can be used in the practice or testing of the present invention, the preferred methods, equipment and materials are described in the present invention.
[0093] Norfloxacin cocrystals can be identified by a variety of technical means, such as X-ray powder diffraction (PXRD), infrared absorption spectroscopy (IR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), nuclear magnetic resonance, X-ray single crystal diffraction, etc.
[0094] X-ray powder diffraction (XRPD) can detect information such as changes in crystal forms, crystallinity, and crystalline state, and is a common means of identifying crystal forms. The peak position of the XRPD spectrum depends mainly on the structure of the crystal form and is relatively insensitive to experimental details, while its relative peak height depends on many factors related to sample preparation and instrument geometry. Therefore, in some embodiments, the crystal form of the present invention is characterized by an XRPD pattern with certain peaks, which is basically as shown in the XRPD pattern provided in the accompanying drawings of the present invention. At the same time, the measurement of 2θ of the XRPD spectrum may have experimental errors, and the measurement of 2θ of the XRPD spectrum may be slightly different between different instruments and different samples. Therefore, the value of 2θ cannot be regarded as absolute. According to the instrument conditions used in this experiment, the diffraction peak has an error tolerance of ±0.2°.
[0095] Differential scanning calorimetry (DSC) is a technique that measures the energy difference between a sample and an inert reference material (usually α-Al2O3) as it changes with temperature by continuous heating or cooling under program control. The height of the endothermic peak of the DSC curve depends on many factors related to sample preparation and instrument geometry, while the peak position is relatively insensitive to experimental details. Therefore, in some embodiments, the co-crystal of the present invention is characterized by a DSC graph with a characteristic peak position, which is basically as shown in the DSC graph provided in the accompanying drawings of the present invention. At the same time, the DSC spectrum may have experimental errors. The peak position and peak value of the DSC spectrum may vary slightly between different instruments and different samples. Therefore, the peak position or peak value of the DSC endothermic peak cannot be regarded as absolute. According to the instrument conditions used in this experiment, the endothermic peak has an error tolerance of ±3°C.
[0096] Thermogravimetric analysis (TGA) is a technique that measures the mass change of a substance with temperature under program control. It is suitable for checking the loss of solvent in crystals or the process of sample sublimation and decomposition. It can infer the presence of crystal water or crystallization solvent in the crystals. The mass change shown by the TGA curve depends on many factors such as sample preparation and instrumentation. The mass change detected by TGA varies slightly between different instruments and different samples. According to the instrument conditions used in this experiment, the mass change has an error tolerance of ±0.5
[0097] In the context of the present invention, 2θ values in X-ray powder diffraction patterns are given in degrees (°).
[0098] The term "peak" when referring to a spectrum and / or data appearing therein refers to a feature that can be identified by one skilled in the art and which cannot be attributed to background noise.
[0099] The present invention relates to said norfloxacin cocrystals, which are in a substantially pure crystalline form.
[0100] "Substantially pure" means that one crystalline form is substantially free of one or more other crystalline forms, that is, the purity of the crystalline form is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.6%, or at least 99.7%, or at least 99.8%, or at least 99.9%, or the crystalline form contains other crystalline forms, and the percentage of the other crystalline forms in the total volume or total weight of the crystalline form is less than 20%, or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.
[0101] "Substantially free" means that the percentage of one or more other crystalline forms in the total volume or total weight of the crystalline form is less than 20%, or less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.
[0102] The "relative intensity" (or "relative peak height") in the XRPD pattern refers to the ratio of the intensity of other peaks to the intensity of the first strongest peak among all diffraction peaks in the X-ray powder diffraction pattern (XRPD) when the intensity of the first strongest peak is 100%.
[0103] In the present invention, "room temperature" refers to a temperature from about 10°C to about 40°C. In some embodiments, "room temperature" refers to a temperature from about 20°C to about 30°C; in other embodiments, "room temperature" refers to 20°C, 22.5°C, 25°C, 27.5°C, etc.
[0104] Unless otherwise specified in the parameters, all analyses below were performed at room temperature.
[0105] X-ray powder diffraction (XRPD) was performed on the cocrystals in the examples using a Rigaku Ultima IV powder diffractometer, which used a Cu target irradiation (40 kV, 40 mA) and a D / tex Ultra detector at room temperature. The scanning range was from 3° to 45° in the 2θ interval, and the scanning speed was 20° / min.
[0106] The eutectic or salt in the embodiment was subjected to differential scanning calorimetry (DSC) analysis, and the operation and analysis steps were as follows: TAQ2000 differential scanning calorimeter was used, N2 atmosphere was adopted, and the heating rate was 10°C / min. In the DSC graph, the horizontal axis represents temperature (Temperature, ℃), and the vertical axis represents the heat flow (HeatFlow, W / g) released by unit mass of the substance.
[0107] The eutectic in the embodiment was subjected to thermogravimetric (TGA) analysis, and the operation and analysis steps were as follows: TAQ500 thermogravimetric analyzer was used, N2 atmosphere was adopted, and the heating rate was 10°C / min. In the TGA graph, the horizontal axis represents temperature (Temperature, ℃), and the vertical axis represents mass percentage (Weight, %).
[0108] The dissolution analysis of the cocrystal in the embodiment was performed, and the operation and analysis steps were as follows: Agilent 1260 series high performance liquid chromatograph was used, and the chromatographic column was C18 column, wherein the mobile phase of norfloxacin was 0.1% phosphoric acid solution (adjusted to pH 3.5 with triethylamine)-acetonitrile (70:30), the flow rate was 1.0 mL / min, the column temperature was 40°C, the injection volume was 20 μL, and the wavelength was 205 nm. The mobile phase of resveratrol was water-acetonitrile (70:30), the flow rate was 1.0 mL / min, the column temperature was 35°C, the injection volume was 20 μL, and the wavelength was 306 nm.
[0109] The single crystal X-ray diffraction (SCXRD) analysis in the embodiment was performed as follows: a Bruker D8 Venture (Bruker, Karlsruhe, Germany) diffractometer was used under Cu-Kα radiation. Diffraction data were collected using CCD, data integration and reduction were performed using APEX3 software, the structure was solved by direct methods using OLEX2 software and refined by full-matrix least-squares using the SHELXL program.
[0110] The model of the polarized light microscope is DM750P, and the model of the heating device is XRN-350.
[0111] The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiment. Any equivalent modifications or changes made by ordinary technicians in this field based on the contents disclosed by the present invention should be included in the protection scope recorded in the claims.
Claims
1. A norfloxacin cocrystal having advantages in hygroscopicity and permeability, characterized in that: The invention comprises a co-crystal formed by combining norfloxacin with a co-crystal former, wherein the co-crystal former is resveratrol, namely, norfloxacin-resveratrol co-crystal. A hemostatic sponge with antibacterial and healing-promoting effects, characterized in that it comprises a hemostatic sponge formed by a composite of gelatin and sodium alginate loaded with a norfloxacin-resveratrol eutectic, i.e., a eutectic-loaded gelatin-sodium alginate hemostatic sponge, which has good antibacterial and healing-promoting activity, good biosafety and good hemostatic performance.
2. The norfloxacin cocrystal having advantages in hygroscopicity and permeability according to claim 1, characterized in that: The X-ray powder diffraction spectrum of the norfloxacin-resveratrol cocrystal has a characteristic peak represented by an angle 2θ (°): 5.84, 6.64, 7.90, 9.74, 12.06, 13.26, 13.58, 14.10, 15.02, 15.58, 16.32, 16.70, 18.66, 19.16, 19.74, 20.55, 20.86, 21.94, 22.64, 22.92, 24.06, 25.00, 25.48, 25.90, 26.32, 26.70, 27.78, 28.46, 29.58, 29.88, 30.96, 31.92, 32.50, 35.81, 39.42, 40.88, 41.96, with an error tolerance of ±0.2°.
3. The norfloxacin cocrystal having advantages in hygroscopicity and permeability according to claim 1, characterized in that: The thermogravimetric analysis (TGA) spectrum of the norfloxacin-resveratrol co-crystal shows that a weight loss of 4.56% occurs at 37-100° C., which is attributed to a desolvation phenomenon, and the co-crystal is a hydrate.
4. The norfloxacin cocrystal having advantages in hygroscopicity and permeability according to claim 1, characterized in that: The differential scanning calorimetry spectrum of the norfloxacin-resveratrol cocrystal shows that peak = There is an endothermic peak at 95.49℃, which is attributed to the desolvation endothermic peak.
5. The norfloxacin cocrystal having advantages in hygroscopicity and permeability according to claim 1, characterized in that: In the norfloxacin-resveratrol co-crystal, norfloxacin and resveratrol exist in a molar ratio of 2:0.
5.
6. The hemostatic sponge with antibacterial and healing-promoting effects according to claim 1, characterized in that: The eutectic-loaded gelatin-sodium alginate hemostatic sponge has a liquid absorption rate of 10.11, a porosity of 0.96, a shape fixation ratio of 0.39, and a shape recovery ratio of 0.
75.
7. The method for preparing the powder of norfloxacin-resveratrol cocrystal according to any one of claims 1 to 5, characterized in that: The specific steps are as follows: weigh equimolar amounts of norfloxacin (100 mg) and resveratrol (94 mg), add 5 mL of ethanol and 0.2 mL of water, stir on a magnetic stirrer at room temperature for 24 hours to obtain a white turbid liquid, then centrifuge it at 8000 r for 5 minutes, discard the supernatant, and dry the precipitate in a 50°C vacuum drying oven to obtain a white powder.
8. The method for preparing the eutectic-loaded gelatin-sodium alginate hemostatic sponge according to claim 6, characterized in that: The specific steps are as follows: add 20 mg / mL gelatin and 20 mg / mL sodium alginate at room temperature for limited swelling, heat and stir, and then stand to remove bubbles, freeze at -80°C for 12 hours and then vacuum for 12 hours, soak the freeze-dried sample in 20 mg / mL calcium chloride aqueous solution for 2 hours for cross-linking, and freeze-dry again to obtain a white gelatin-sodium alginate hemostatic sponge. Norfloxacin-resveratrol cocrystals are loaded by the immersion method to obtain cocrystal-loaded gelatin-sodium alginate hemostatic sponges.
9. Use of a eutectic-loaded gelatin-sodium alginate hemostatic sponge according to any one of claims 1 to 6, characterized in that: The co-crystal formed by norfloxacin and resveratrol is a pharmaceutically acceptable co-crystal former synthesized co-crystal, which has the dual effects of antibacterial and promoting healing, and also has good hygroscopicity and permeability. It is combined with a hemostatic sponge with good biosafety and hemostatic effect to become a highly effective hemostatic sponge preparation with dual effects of antibacterial and promoting healing.
